Physician profile
Paula Seth
NPI 1235119637
$2,491.37
in general payments reported to CMS, 2019-2025
21 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $456 · 2021: $137 · 2022: $330 · 2023: $682 · 2024: $457 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $455.03 | 2021-2024 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $364.06 | 2019-2025 | |
| Pfizer INC. | $278.27 | 2019-2025 | |
| Abbott Laboratories | $263.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $220.05 | 2020-2023 | Xarelto |
| Amgen INC. | $192.28 | 2019-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals, LTD. | $143.92 | 2022-2023 | Arcalyst |
| Amarin Pharma, INC. | $83.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.23 | 2022-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $71.27 | 2019-2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $68.00 | 2024 | Arcalyst |
| Novo Nordisk INC | $44.84 | 2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $40.84 | 2022 | |
| Boston Scientific Corporation | $35.23 | 2019-2020 | |
| Tactile Systems Technology INC | $28.67 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.68 | 2025 | Wainua |
| Cvrx, INC. | $26.93 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.84 | 2024 | Lifevest |
| Esperion Therapeutics, INC. | $20.88 | 2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $17.16 | 2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.